Identification of Dihydrobenzofuran Neolignans as Novel PDE4 Inhibitors and Evaluation of Antiatopic Dermatitis Efficacy in DNCB-Induced Mice Model
作者:Chenming Gu、Jiayuan Liu、Fei Qian、Wenchao Yu、Doudou Huang、Jingshan Shen、Chenguo Feng、Kaixian Chen、Yiming Li、Xiangrui Jiang、Yechun Xu、Liuqiang Zhang
DOI:10.1021/acs.jmedchem.3c02424
日期:2024.3.28
Atopic dermatitis is a chronic relapsing skin disease characterized by recurrent, pruritic, localized eczema, while PDE4 inhibitors have been reported to be effective as antiatopic dermatitis agents. 3′,4-O-dimethylcedrusin (DCN) is a natural dihydrobenzofuran neolignan isolated from Magnolia biondii with moderate potency against PDE4 (IC50 = 3.26 ± 0.28 μM) and a binding mode similar to that of apremilast
特应性皮炎是一种慢性复发性皮肤病,其特征是复发性、瘙痒性、局部湿疹,而据报道,PDE4抑制剂作为抗特应性皮炎药物是有效的。 3',4- O-二甲基雪松素 (DCN) 是一种从木兰中分离出来的天然二氢苯并呋喃新木脂素,具有中等的抗 PDE4 效力 (IC 50 = 3.26 ± 0.28 μM),其结合模式类似于阿普斯特(一种已批准用于治疗的 PDE4 抑制剂)。治疗牛皮癣。基于DCN的结构优化,鉴定出7b-1 ,其对PDE4表现出高抑制效力(IC 50 = 0.17 ± 0.02 μM),良好的抗TNF-α活性(EC 50 = 0.19 ± 0.10 μM),显着选择性分布和良好的皮肤渗透性。 7b-1的局部治疗在 DNCB 诱导的特应性皮炎样小鼠模型中产生了显着的药物干预益处,证明了其开发新型抗特应性皮炎药物的潜力。